Keenova Presents TERLIVAZ Data for Transplant-Ineligible HRS-AKI
Dublin – October 12, 2026 -- Keenova Therapeutics plc will present an exploratory analysis of the CONFIRM trial on October 12 at the American College of Gastroenterology Annual Meeting (October 9-14, 2026). The analysis covers TERLIVAZ (terlipressin) in hepatorenal syndrome-acute kidney injury (HRS-AKI) patients who are ineligible for liver transplant.
Ten-author analysis targets liver transplant-ineligible patients
The presentation is titled "Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial." Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center, is the presenting author. Nine co-authors are listed, including Kavish Patidar, Kevin Regner and Nneka N. Ufere.